Lake Street Capital began coverage on shares of Novogen (NASDAQ:KZIA – Get Free Report) in a report released on Thursday. The firm set a “buy” rating and a $32.00 price target on the stock. Lake Street Capital’s price target would suggest a potential upside of 178.26% from the stock’s previous close.
Several other research firms have also commented on KZIA. Wall Street Zen lowered Novogen from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Laidlaw assumed coverage on Novogen in a research report on Wednesday, April 15th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.75.
View Our Latest Research Report on Novogen
Novogen Trading Up 0.7%
Novogen (NASDAQ:KZIA – Get Free Report) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($1.34) EPS for the quarter. The company had revenue of $4.89 million for the quarter. As a group, research analysts expect that Novogen will post -0.01 earnings per share for the current fiscal year.
Novogen Company Profile
Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.
Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.
Featured Articles
- Five stocks we like better than Novogen
- Wolfspeed Ditches EV Woes for High-Margin Defense Jets
- Casey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance Align
- The “Duck Stock” Keeps Quietly Making Money for Shareholders
- As Shares Fall, Analyst Are Boosting their Broadcom Price Targets
Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.
